RAB37

Summary

RAB37 (RAB37, member RAS oncogene family, HGNC:30268) is a protein-coding gene on chromosome 17q25.1, encoding Ras-related protein Rab-37 (Q96AX2). The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes.

Rab proteins are low molecular mass GTPases that are critical regulators of vesicle trafficking. For additional background information on Rab proteins, see MIM 179508.

Source: NCBI Gene 326624 — RefSeq curated summary.

At a glance

• GWAS associations: 21
• Clinical variants (ClinVar): 56 total
• MANE Select transcript: NM_001006638

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30268
Approved symbol	RAB37
Name	RAB37, member RAS oncogene family
Location	17q25.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000172794
Ensembl biotype	protein_coding
OMIM	609956
Entrez	326624

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 10 protein_coding, 6 retained_intron, 1 nonsense_mediated_decay

ENST00000340415, ENST00000392610, ENST00000392612, ENST00000392613, ENST00000392614, ENST00000392615, ENST00000392617, ENST00000402449, ENST00000481224, ENST00000488977, ENST00000527040, ENST00000528438, ENST00000531420, ENST00000533530, ENST00000577548, ENST00000613645, ENST00000872455

RefSeq mRNA: 5 — MANE Select: NM_001006638 NM_001006638, NM_001163989, NM_001163990, NM_001330471, NM_175738

CCDS: CCDS11703, CCDS32722, CCDS54162, CCDS82198

Canonical transcript exons

ENST00000392613 — 9 exons

Exon	Start	End
ENSE00001196836	74744873	74744929
ENSE00001196840	74744308	74744373
ENSE00001258832	74737256	74737365
ENSE00001431713	74745306	74747335
ENSE00003462631	74742254	74742295
ENSE00003504490	74743288	74743340
ENSE00003581199	74745008	74745084
ENSE00003595334	74740768	74740878
ENSE00003655108	74743129	74743195

Expression profiles

Bgee: expression breadth ubiquitous, 180 present calls, max score 97.12.

FANTOM5 (CAGE): breadth broad, TPM avg 10.1300 / max 426.2672, expressed in 577 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
162653	6.2972	430
162652	3.2663	378
162647	0.4309	71
162650	0.0439	10
162651	0.0385	6
162648	0.0232	5
162646	0.0222	9
162649	0.0079	4

Top tissues by expression

245 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cerebellar hemisphere	UBERON:0002245	97.12	gold quality
cerebellar cortex	UBERON:0002129	96.99	gold quality
right hemisphere of cerebellum	UBERON:0014890	96.81	gold quality
granulocyte	CL:0000094	96.56	gold quality
cerebellum	UBERON:0002037	96.06	gold quality
leukocyte	CL:0000738	94.98	gold quality
monocyte	CL:0000576	94.85	gold quality
blood	UBERON:0000178	93.86	gold quality
nasal cavity epithelium	UBERON:0005384	89.24	gold quality
spleen	UBERON:0002106	86.75	gold quality
bone marrow cell	CL:0002092	85.47	gold quality
right lobe of liver	UBERON:0001114	85.25	gold quality
endothelial cell	CL:0000115	85.23	gold quality
palpebral conjunctiva	UBERON:0001812	84.84	gold quality
right frontal lobe	UBERON:0002810	84.50	gold quality
pancreatic ductal cell	CL:0002079	83.96	silver quality
lymph node	UBERON:0000029	83.34	gold quality
bone marrow	UBERON:0002371	83.10	gold quality
vermiform appendix	UBERON:0001154	82.86	gold quality
mucosa of transverse colon	UBERON:0004991	82.68	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	81.94	gold quality
prefrontal cortex	UBERON:0000451	81.92	gold quality
apex of heart	UBERON:0002098	81.79	gold quality
Brodmann (1909) area 9	UBERON:0013540	81.53	gold quality
anterior cingulate cortex	UBERON:0009835	81.31	gold quality
small intestine Peyer’s patch	UBERON:0003454	81.11	gold quality
nasal cavity mucosa	UBERON:0001826	80.05	gold quality
primary visual cortex	UBERON:0002436	79.79	gold quality
frontal cortex	UBERON:0001870	78.62	gold quality
mucosa of stomach	UBERON:0001199	78.34	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-6701	yes	9.75
E-ANND-3	yes	7.74
E-MTAB-6678	no	3.90

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

84 targeting RAB37, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-329-3P	99.91	66.56	1234
HSA-MIR-362-3P	99.91	66.38	1267
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-4779	99.86	66.50	1583
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-544A	99.84	68.66	1965
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-6842-5P	99.80	67.54	1587
HSA-MIR-7110-5P	99.80	67.84	1712
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-12129	99.72	67.45	1311
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-30B-3P	99.70	65.76	2325
HSA-MIR-3689A-3P	99.70	65.73	2306
HSA-MIR-3689B-3P	99.70	65.71	2311
HSA-MIR-3689C	99.70	65.71	2311
HSA-MIR-6779-5P	99.70	65.76	2363
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-3618	99.69	68.57	1012
HSA-MIR-1283	99.69	72.42	3009
HSA-MIR-488-3P	99.61	68.79	1731
HSA-MIR-1260A	99.61	66.67	1098
HSA-MIR-1260B	99.61	66.67	1098
HSA-MIR-17-3P	99.55	66.77	1311

Literature-anchored findings (GeneRIF, showing 12)

• Promoter/exon1 methylation is the predominant mechanism in down-regulation of the hRAB37, and can serve as a potential prediction biomarker of NSCLC progression. (PMID:18687502)
• the TMEM22/RAB37 complex is likely to play a crucial role in growth of renal cell carcinoma (PMID:19148500)
• Rab37 mRNA was specifically expressed in some ESCC cell lines but its genetic polymorphisms were not associated with esophageal squamous cell carcinoma. (PMID:23372429)
• Results identify Rab37 as an additional component of the machinery governing exocytosis of beta-cells and suggest that impaired expression of this GTPase may contribute to defective insulin release in pre-diabetic and diabetic conditions. (PMID:23826383)
• RAB37 regulates the exocytosis of TIMP1 in a nucleotide-dependent manner to inactivate MMP9 migration axis in vitro and in vivo and to suppress tumor metastasis. (PMID:25183545)
• Our findings suggest that Rab37-mediated TSP1 secretion in cancer cells suppresses metastasis and angiogenesis via a cross-talk with endothelial cells and reveal a novel component of the vesicular exocytic machinery in tumor microenvironment and tumor progression (PMID:28151721)
• results demonstrate a role of RAB37 in autophagosome formation through a molecular connection of RAB37, ATG5-12, ATG16L1 up to LC3B, suggesting an organiser role of RAB37 during autophagosomal membrane biogenesis. (PMID:29229996)
• Low RAB37 expression is associated with lung cancer. (PMID:29717487)
• This study shows that RAB37 hypermethylation is involved in NPC metastasis and chemoresistance, and that our prognostic model can identify patients who are at a high risk of distant metastasis and might benefit from for docetaxel IC. (PMID:30131385)
• Rab37-mediated SFRP1 secretion suppresses cancer stemness. (PMID:30158579)
• Findings indicate that patients with low vesicle associated membrane protein 8 (VAMP8)/low rab GTP-binding protein RAB37 (RAB37) expression profile showed significantly high risk of death even after adjusting for tumor metastasis parameter. (PMID:30165196)
• Methionine represses the autophagy of gastric cancer stem cells via promoting the methylation and phosphorylation of RAB37. (PMID:32926650)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Rab37	ENSMUSG00000020732
rattus_norvegicus	Rab37	ENSRNOG00000059793

Paralogs (68): RAB27B (ENSG00000041353), RAB27A (ENSG00000069974), RAB7A (ENSG00000075785), RABL2B (ENSG00000079974), RAB21 (ENSG00000080371), RAB10 (ENSG00000084733), RAB18 (ENSG00000099246), RAB36 (ENSG00000100228), IFT27 (ENSG00000100360), RAB40AL (ENSG00000102128), RAB11A (ENSG00000103769), RAB2A (ENSG00000104388), RAB3D (ENSG00000105514), RAB3A (ENSG00000105649), RAB5C (ENSG00000108774), RAB34 (ENSG00000109113), RAB5B (ENSG00000111540), RAB35 (ENSG00000111737), RAB23 (ENSG00000112210), DNAJC27 (ENSG00000115137), RAB29 (ENSG00000117280), RAB32 (ENSG00000118508), RAB14 (ENSG00000119396), RAB9B (ENSG00000123570), RAB9A (ENSG00000123595), RAB38 (ENSG00000123892), RAB22A (ENSG00000124209), RAB17 (ENSG00000124839), RAB2B (ENSG00000129472), RAB25 (ENSG00000132698), RAB33A (ENSG00000134594), RAB30 (ENSG00000137502), RAB1A (ENSG00000138069), RAB20 (ENSG00000139832), RAB15 (ENSG00000139998), RAB40B (ENSG00000141542), RAB13 (ENSG00000143545), RABL2A (ENSG00000144134), RAB5A (ENSG00000144566), RAB19 (ENSG00000146955)

Protein

Protein identifiers

Ras-related protein Rab-37 — Q96AX2 (reviewed: Q96AX2)

All UniProt accessions (6): A0A9H3ZVF6, A8MSP2, A8MTC6, A8MZI4, B7Z3L0, Q96AX2

UniProt curated annotations — full annotation on UniProt →

Function. The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes. Rabs cycle between an inactive GDP-bound form and an active GTP-bound form that is able to recruit to membranes different sets of downstream effectors directly responsible for vesicle formation, movement, tethering and fusion. Acts as an organizer for autophagosome biogenesis in a GTP-dependent manner. Involved in retinal homeostasis by autophagy regulation.

Subunit / interactions. Interacts with RIMS1. Interacts (in GDP-bound form) with RPGR, RPGR functions as guanine exchange factor (GEF).

Subcellular location. Cytoplasmic vesicle. Cell projection. Cilium.

Activity regulation. Regulated by guanine nucleotide exchange factors (GEFs) including RPGR which promote the exchange of bound GDP for free GTP. Regulated by GTPase activating proteins (GAPs) which increase the GTP hydrolysis activity. Inhibited by GDP dissociation inhibitors (GDIs).

Domain organisation. Switch 1, switch 2 and the interswitch regions are characteristic of Rab GTPases and mediate the interactions with Rab downstream effectors. The switch regions undergo conformational changes upon nucleotide binding which drive interaction with specific sets of effector proteins, with most effectors only binding to GTP-bound Rab.

Similarity. Belongs to the small GTPase superfamily. Rab family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q96AX2-1	1	yes
Q96AX2-2	2
Q96AX2-3	3
Q96AX2-4	4

RefSeq proteins (5): NP_001006639, NP_001157461, NP_001157462, NP_001317400, NP_783865 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001806	Small_GTPase	Family
IPR005225	Small_GTP-bd	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily

Pfam: PF00071

Enzyme classification (BRENDA):

• EC 3.6.5.2 — small monomeric GTPase (BRENDA: 49 organisms, 138 substrates, 55 inhibitors, 5 Km, 1 kcat entries)

Substrate kinetics (BRENDA)

1 substrates with measured Km, best-characterized 1. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
GTP	—	0

Catalyzed reactions (Rhea), 1 shown:

• GTP + H2O = GDP + phosphate + H(+) (RHEA:19669)

UniProt features (35 total): binding site 19, splice variant 3, modified residue 2, lipid moiety-binding region 2, mutagenesis site 2, short sequence motif 2, initiator methionine 1, chain 1, propeptide 1, region of interest 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96AX2-F1	84.42	0.57

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (19): 42; 43; 43; 44; 62; 62; 85; 88; 143; 144; 146; 147 …

Post-translational modifications (4): 2, 220, 219, 220

Mutagenesis-validated functional residues (2):

Position	Phenotype
43	stimulates interaction with rpgr. loss of exchange between rab37-gdp to rab37-gtp.
89	decreased interaction with rpgr. loss of exchange between rab37-gdp to rab37-gtp.

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-6798695	Neutrophil degranulation
R-HSA-8873719	RAB geranylgeranylation

MSigDB gene sets: 209 (showing top): GOBP_REGULATION_OF_AUTOPHAGY, REACTOME_INNATE_IMMUNE_SYSTEM, GOCC_VACUOLAR_MEMBRANE, GOCC_SECRETORY_GRANULE, GOBP_REGULATION_OF_EXOCYTOSIS, GOBP_NEUROGENESIS, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_REGULATION_OF_VESICLE_MEDIATED_TRANSPORT, GOBP_EXOCYTOSIS, GOBP_ANIMAL_ORGAN_MORPHOGENESIS, GOBP_EYE_PHOTORECEPTOR_CELL_DIFFERENTIATION, GOBP_REGULATION_OF_CATABOLIC_PROCESS, GOBP_REGULATION_OF_NEURON_DIFFERENTIATION, GOBP_POSITIVE_REGULATION_OF_CATABOLIC_PROCESS, GGARNTKYCCA_UNKNOWN

GO Biological Process (4): positive regulation of autophagy (GO:0010508), protein transport (GO:0015031), regulation of exocytosis (GO:0017157), regulation of eye photoreceptor cell development (GO:0042478)

GO Molecular Function (7): GTPase activity (GO:0003924), G protein activity (GO:0003925), GTP binding (GO:0005525), metal ion binding (GO:0046872), nucleotide binding (GO:0000166), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (10): endosome (GO:0005768), endoplasmic reticulum-Golgi intermediate compartment (GO:0005793), Golgi apparatus (GO:0005794), plasma membrane (GO:0005886), photoreceptor connecting cilium (GO:0032391), azurophil granule membrane (GO:0035577), specific granule membrane (GO:0035579), cilium (GO:0005929), cytoplasmic vesicle (GO:0031410), cell projection (GO:0042995)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Innate Immune System	1
Post-translational protein modification	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	3
endomembrane system	2
intracellular membrane-bounded organelle	2
secretory granule membrane	2
autophagy	1
positive regulation of catabolic process	1
regulation of autophagy	1
transport	1
intracellular protein localization	1
establishment of protein localization	1
exocytosis	1
regulation of vesicle-mediated transport	1
regulation of secretion by cell	1
eye photoreceptor cell development	1
regulation of photoreceptor cell differentiation	1
regulation of cell development	1
ribonucleoside triphosphate phosphatase activity	1
GTPase activity	1
molecular function regulator activity	1
guanyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
cation binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
catalytic activity	1
cytoplasmic vesicle	1
membrane	1
cell periphery	1
ciliary transition zone	1
photoreceptor cell cilium	1
lysosomal membrane	1
azurophil granule	1
specific granule	1
intraciliary transport particle	1
membrane-bounded organelle	1
plasma membrane bounded cell projection	1
intracellular vesicle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

360 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RAB37	ATG5	Q9H1Y0	596
RAB37	RAB32	Q13637	443
RAB37	INS	P01308	386
RAB37	SLC35G2	Q8TBE7	375
RAB37	UNC13D	Q70J99	348
RAB37	VAMP7	P51809	320
RAB37	TBC1D14	Q9P2M4	300
RAB37	PLVAP	Q9BX97	286
RAB37	SYTL4	Q96C24	273
RAB37	SYTL2	Q9HCH5	270
RAB37	VAMP3	Q15836	260
RAB37	VTI1B	Q9UEU0	253
RAB37	RPH3AL	Q9UNE2	245
RAB37	SYCE1L	A8MT33	237
RAB37	GPR142	Q7Z601	235

IntAct

11 interactions, top by confidence:

A	B	Type	Score
RAB37	MAL2	psi-mi:“MI:0915”(physical association)	0.560
MAL2	RAB37	psi-mi:“MI:0915”(physical association)	0.560
RAB37	RABGGTB	psi-mi:“MI:0915”(physical association)	0.490
RAB37	H2AC20	psi-mi:“MI:0915”(physical association)	0.400
EWSR1	RAB37	psi-mi:“MI:0915”(physical association)	0.370
PB2		psi-mi:“MI:0914”(association)	0.350
RAB37	ESPN	psi-mi:“MI:0914”(association)	0.350
ubiF	RAB37	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (12): RAB37 (Two-hybrid), RAB37 (Two-hybrid), RAB37 (Two-hybrid), RAB37 (Affinity Capture-MS), RAB37 (Affinity Capture-MS), RAB37 (Affinity Capture-RNA), ESPN (Affinity Capture-MS), MICAL1 (Affinity Capture-MS), HIST2H2AC (Affinity Capture-MS), RAB37 (Two-hybrid), RAB37 (Protein-RNA), RAB37 (Protein-RNA)

ESM2 similar proteins: A4D1S5, O13876, O80501, P05714, P10948, P10949, P20337, P20338, P34213, P35289, P35293, P35294, P51152, P51159, P56371, P62823, P90726, Q05976, Q0IIG8, Q15771, Q17QB7, Q18969, Q1HE58, Q28IZ3, Q2TBH7, Q32NQ0, Q3ZC27, Q53B90, Q54E92, Q55FK2, Q5EB77, Q5KTJ7, Q5M7U5, Q5R5H5, Q63941, Q68EK7, Q6DHC1, Q6PHI9, Q8CG50, Q923S9

Diamond homologs: A4FV54, C4YL11, F1PTE3, O24466, O42819, O76173, O95716, P01123, P07560, P0CY30, P0CY31, P10536, P10949, P11023, P11620, P16976, P17609, P20336, P20790, P20791, P22125, P22127, P22128, P24409, P25228, P28186, P28188, P31584, P33723, P34139, P34140, P35276, P35280, P35281, P35286, P35289, P36861, P40392, P41924, P51153

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
PRKCA	“down-regulates activity”	RAB37	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

56 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	39
Likely benign	7
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2595 predictions. Top by Δscore:

Variant	Effect	Δscore
17:74695720:CGCA:C	donor_loss	1.0000
17:74695743:TTC:T	donor_loss	1.0000
17:74695744:T:TA	donor_gain	1.0000
17:74695861:T:G	acceptor_loss	1.0000
17:74704472:TCTTA:T	donor_loss	1.0000
17:74704473:CTTAC:C	donor_loss	1.0000
17:74704474:TTA:T	donor_loss	1.0000
17:74704475:TACCT:T	donor_loss	1.0000
17:74704476:A:C	donor_loss	1.0000
17:74704477:C:G	donor_loss	1.0000
17:74712819:CTCA:C	donor_loss	1.0000
17:74712820:TCA:T	donor_loss	1.0000
17:74712821:CAC:C	donor_loss	1.0000
17:74712822:ACCTG:A	donor_loss	1.0000
17:74712823:C:A	donor_loss	1.0000
17:74737057:G:GT	donor_gain	1.0000
17:74737058:G:T	donor_gain	1.0000
17:74737108:G:T	donor_gain	1.0000
17:74740877:GG:G	donor_gain	1.0000
17:74740877:GGGT:G	donor_loss	1.0000
17:74740878:GG:G	donor_gain	1.0000
17:74740878:GGTG:G	donor_loss	1.0000
17:74740880:T:G	donor_loss	1.0000
17:74742293:CAG:C	donor_loss	1.0000
17:74742294:AG:A	donor_loss	1.0000
17:74742295:GGTGA:G	donor_loss	1.0000
17:74742296:G:A	donor_loss	1.0000
17:74743124:CCCAG:C	acceptor_loss	1.0000
17:74743125:CCA:C	acceptor_loss	1.0000
17:74743126:CAG:C	acceptor_loss	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000080033 (17:74745241 G>A,C), RS1000108071 (17:74714710 A>G), RS1000124556 (17:74691526 C>T), RS1000193738 (17:74735877 C>A), RS1000201688 (17:74730115 C>A), RS1000256973 (17:74686658 T>A,C), RS1000301968 (17:74729973 G>A), RS1000379274 (17:74709085 G>A), RS1000403511 (17:74680571 G>A), RS1000410826 (17:74735434 G>C,T), RS1000417750 (17:74703474 C>T), RS1000460909 (17:74692950 G>C), RS1000511810 (17:74747521 G>C,T), RS1000530457 (17:74729151 T>A), RS1000536672 (17:74692010 C>T)

Disease associations

OMIM: gene MIM:609956 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

21 associations (top):

Study	Trait	p-value
GCST004122_30	Fibrinogen levels	2.000000e-08
GCST004610_84	White blood cell count	9.000000e-14
GCST004613_59	Sum neutrophil eosinophil counts	3.000000e-09
GCST004614_66	Granulocyte count	3.000000e-09
GCST004620_101	Sum basophil neutrophil counts	4.000000e-09
GCST004625_248	Monocyte count	4.000000e-24
GCST004626_149	Myeloid white cell count	2.000000e-11
GCST004629_35	Neutrophil count	5.000000e-09
GCST004938_5	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease	9.000000e-06
GCST005196_226	Coronary artery disease	1.000000e-07
GCST007614_36	C-reactive protein levels	4.000000e-14
GCST008478_46	Neurological blood protein biomarker levels	1.000000e-21
GCST008478_47	Neurological blood protein biomarker levels	5.000000e-12
GCST008478_48	Neurological blood protein biomarker levels	3.000000e-77
GCST008478_49	Neurological blood protein biomarker levels	2.000000e-11
GCST008478_51	Neurological blood protein biomarker levels	5.000000e-15
GCST008478_52	Neurological blood protein biomarker levels	1.000000e-16
GCST90002393_611	Monocyte count	5.000000e-30
GCST90002400_230	Plateletcrit	5.000000e-18
GCST90002402_415	Platelet count	7.000000e-17
GCST90002407_146	White blood cell count	4.000000e-18

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0004833	neutrophil count
EFO:0004842	eosinophil count
EFO:0007987	granulocyte count
EFO:0005090	basophil count
EFO:0005091	monocyte count
EFO:0004458	C-reactive protein measurement
EFO:0007985	platelet crit
EFO:0004309	platelet count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

46 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases methylation, increases expression	4
Valproic Acid	increases expression, increases methylation, affects expression	3
entinostat	increases expression	2
Tobacco Smoke Pollution	affects expression, increases methylation	2
GSK-J4	decreases expression	1
aminomethylphosphonic acid (AMPA)	decreases expression	1
terbufos	increases methylation	1
trichostatin A	increases expression	1
arsenite	increases methylation	1
benzo(e)pyrene	increases methylation	1
S-(1,2-dichlorovinyl)cysteine	decreases expression, affects cotreatment	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
nutlin 3	affects cotreatment, increases expression	1
abrine	decreases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	decreases reaction, increases expression	1
perfluorobutanesulfonic acid	increases expression	1
jinfukang	affects cotreatment, increases expression	1
bis-N,N-dimethylamino-2-(N-methylpyrrolyl)methyl cyclopentadienyl titanium (IV)	increases expression	1
(+)-JQ1 compound	decreases expression	1
Acetaminophen	decreases expression	1
Arsenic	affects methylation	1
Vehicle Emissions	decreases reaction, increases expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Camptothecin	increases expression	1
Cisplatin	affects cotreatment, increases expression	1
Cytarabine	decreases expression	1
Dactinomycin	affects cotreatment, increases expression	1
Diuron	decreases expression	1
Fonofos	increases methylation	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.